A Randomized Crossover, Phase II Clinical Trial of MK-3475 in Combination With Docetaxel Versus Docetaxel Alone in Patients With Non-Small Cell Lung Cancer (NSCLC) Previously Treated.
Not yet recruiting
Phase of Trial: Phase II
Latest Information Update: 11 Apr 2016
At a glance
- Drugs Pembrolizumab (Primary) ; Docetaxel
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 07 Apr 2016 Planned initiation date changed from 1 Jan 2016 to 1 Jun 2016, as reported by ClinicalTrials.gov record.
- 19 Oct 2015 New trial record